2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705

Arch Virol. 2020 Nov;165(11):2605-2613. doi: 10.1007/s00705-020-04759-4. Epub 2020 Aug 8.

Abstract

Noroviruses are the main causative agents of acute viral gastroenteritis worldwide. However, no vaccine or specific antiviral treatment is available, imposing a heavy global health burden. The nucleoside analogue 2'-fluoro-2'-deoxycytidine (2'-FdC) has been reported to have broad antiviral activity. Here, we report that 2'-FdC significantly inhibits murine norovirus replication in macrophages. This effect was partially reversed by exogenous supplementation of cytidine triphosphate. The combination of 2'-FdC with mycophenolic acid, ribavirin or favipiravir (T705) exerts synergistic antiviral effects. These results indicate that 2'-FdC is a potential candidate for antiviral drug development against norovirus infection.

MeSH terms

  • Amides / pharmacology
  • Animals
  • Antiviral Agents / pharmacology*
  • Caliciviridae Infections / drug therapy
  • Caliciviridae Infections / virology
  • Cell Line
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Humans
  • Mice
  • Mycophenolic Acid / pharmacology
  • Norovirus / drug effects*
  • Norovirus / physiology
  • Pyrazines / pharmacology
  • RAW 264.7 Cells
  • Ribavirin / pharmacology
  • Virus Replication / drug effects*
  • Virus Replication / physiology

Substances

  • Amides
  • Antiviral Agents
  • Pyrazines
  • Deoxycytidine
  • Ribavirin
  • favipiravir
  • Mycophenolic Acid
  • 2'-fluoro-2'-deoxycytidine